HopeStage
Back to all studies
CompletedNCT00448890

Evaluation of Single and Repeat Doses of GSK729327 in Healthy Volunteers

Medication studyAges 18–55Germany + United KingdomSchizophrenia
The study in practice

Understand this study

Who was this study for?

This study was for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Listed locations
Berlin and 1 more locationSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNovember 2006
Recruitment status
Completed
Enrollment listed in the registry
79
Sponsor
GlaxoSmithKline
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United Kingdom, Germany
Age range
From 18 Years to 55 Years
Official registry ID
NCT00448890
Official title
Show the full official title

Single-Blind, Randomised, Placebo-Controlled Two-Part Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Escalating Doses and Repeat Doses of GSK729327 in Healthy Volunteers

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Berlin, Germany · London, United Kingdom

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is GlaxoSmithKline.

Did this study involve medication?

Yes. The study involved medication, including GSK729327 and Placebo.

Who was this study for?

This study was for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies